Article

Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response.

Faculty of Pharmaceutical Sciences, University of Sao Paulo, Sao Paulo 05508-900, Brazil; E-Mails: (P.M.S.P.); (V.N.S.); (F.D.V.G.); (M.A.V.W.); (S.S.A.); (A.D.L.); (M.H.H.); (R.D.C.H.).
International Journal of Molecular Sciences (Impact Factor: 2.46). 01/2011; 12(9):5815-27. DOI: 10.3390/ijms12095815
Source: PubMed

ABSTRACT The relationship between variants in SLCO1B1 and SLCO2B1 genes and lipid-lowering response to atorvastatin was investigated.
One-hundred-thirty-six unrelated individuals with hypercholesterolemia were selected and treated with atorvastatin (10 mg/day/4 weeks). They were genotyped with a panel of ancestry informative markers for individual African component of ancestry (ACA) estimation by SNaPshot(®) and SLCO1B1 (c.388A>G, c.463C>A and c.521T>C) and SLCO2B1 (-71T>C) gene polymorphisms were identified by TaqMan(®) Real-time PCR.
Subjects carrying SLCO1B1 c.388GG genotype exhibited significantly high low-density lipoprotein (LDL) cholesterol reduction relative to c.388AA+c.388AG carriers (41 vs. 37%, p = 0.034). Haplotype analysis revealed that homozygous of SLCO1B1*15 (c.521C and c.388G) variant had similar response to statin relative to heterozygous and non-carriers. A multivariate logistic regression analysis confirmed that c.388GG genotype was associated with higher LDL cholesterol reduction in the study population (OR: 3.2, CI95%:1.3-8.0, p < 0.05).
SLCO1B1 c.388A>G polymorphism causes significant increase in atorvastatin response and may be an important marker for predicting efficacy of lipid-lowering therapy.

1 Bookmark
 · 
253 Views
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is a growing interest among geneticists in developing panels of Ancestry Informative Markers (AIMs) aimed at measuring the biogeographical ancestry of individual genomes. The efficiency of these panels is commonly tested empirically by contrasting self-reported ancestry with the ancestry estimated from these panels.
    BMC genomics. 06/2014; 15(1):543.
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The proprotein convertase subtilisin/kexin type 9 (PCSK9) has a key role in the regulation of plasma low-density lipoprotein (LDL) cholesterol by enhancing the degradation of LDL receptor. Functional variants in PCSK9 have been associated with differences in plasma lipids and may contribute to the variability of the response to cholesterol-lowering drugs. To investigate the influence of PCSK9 variants on plasma lipid profile and response to atorvastatin in Brazilian subjects. PCSK9 E670G, I474V, and R46L single nucleotide polymorphisms (SNPs) and plasma lipids were evaluated in 163 hypercholesterolemics (HC) and 171 normolipidemics (NL). HC patients with indication for cholesterol-lowering drug therapy (n = 128) were treated with atorvastatin (10 mg/d/4 wk). PCSK9 SNPs were analyzed by real time polymerase chain reaction. Frequencies of the PCSK9 SNPs were similar between the HC and NL groups. Logistic regression analysis showed a trend of association between PCSK9 E670G and hypercholesterolemia after adjustment for covariates (P = .059). The 670G allele was associated with high basal levels of LDL cholesterol (P = .03) in HC patients using the extreme discordant phenotype method. No association tests were performed for R46L variant because of its very low frequency, whereas the I474V polymorphism and PCSK9 haplotypes were not related to hypercholesterolemia or variability on plasma lipids in both NL and HC groups (P > .05). LDL cholesterol reduction in response to atorvastatin was not influenced by PCSK9 genotypes or haplotypes. PCSK9 E670G polymorphism but not I474V contributes to the variability on plasma LDL cholesterol levels in hypercholesterolemic subjects. Both PCSK9 variants have no influence on cholesterol-lowering response to atorvastatin.
    Journal of Clinical Lipidology 01/2014; 8(3):256-64. · 3.59 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Interindividual variability in protein expression of organic anion-transporting polypeptides (OATPs), OATP1B1, OATP1B3, OATP2B1, and multidrug resistance -linked P-glycoprotein (P-gp) or ABCB1 was quantified in frozen human livers (n=64) and cryopreserved human hepatocytes (n=12) by a validated LC-MS/MS method. Membrane isolation, sample workup and LC-MS/MS analyses were as described before by our laboratory. Briefly, total native membrane proteins, isolated from the liver tissue and cryopreserved hepatocytes, were trypsin digested and quantified by LC-MS/MS using signature peptide(s) unique to each transporter. The mean ± SD (maximum/minimum range in parentheses) protein expression (fmol/µg of membrane protein) in human liver tissue was, OATP1B1: 2.0±0.9 (7), OATP1B3: 1.1±0.5 (8), OATP2B1: 1.7±0.6 (5), and P-gp: 0.4±0.2 (8). Transporter expression in the liver tissue was comparable to that in the cryopreserved hepatocytes. Most importantly, livers with SLCO1B1 (encoding OATP1B1) haplotypes *14/*14 and *14/*1a (i.e., representing SNPs, c.388A>G, and c.463C>A), had significantly higher (P<0.0001) protein expression than the reference haplotype (*1a/*1a). Based on these genotype-dependent protein expression data, we predicted (using Simcyp) up to ~40% decrease in mean area under the curve (AUC) of rosuvastatin or repaglinide in those individuals harboring these variant alleles compared with those harboring the wild-type alleles. SLCO1B3 (encoding OATP1B3) SNPs did not significantly affect protein expression. Age and sex were not associated with transporter protein expression. These data will facilitate prediction of population-based human transporter-mediated drug disposition, drug-drug interactions, and interindividual variability through PBPK modeling.
    Drug metabolism and disposition: the biological fate of chemicals 10/2013; · 3.74 Impact Factor

Full-text (2 Sources)

View
88 Downloads
Available from
Jun 6, 2014